Literature DB >> 17006986

Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis.

Markus Neumeier1, Claus Hellerbrand, Erwin Gäbele, Roland Buettner, Cornelius Bollheimer, Johanna Weigert, Andreas Schäffler, Thomas S Weiss, Monika Lichtenauer, Jurgen Schölmerich, Christa Buechler.   

Abstract

AIM: To determine circulating and hepatic adiponectin in rodents with fatty liver disease or liver cirrhosis and investigate expression of the adiponectin receptors AdipoR1 on the mRNA and protein level and AdipoR2 on the mRNA level.
METHODS: Fat fed rats were used as a model for fatty liver disease and bile duct ligation in mice to investigate cirrhotic liver. Expression of AdipoR1 and AdipoR2 mRNA was determined by real time RT-PCR. AdipoR1 protein was analysed by immunoblot. Adiponectin was measured by ELISA.
RESULTS: Systemic adiponectin is reduced in fat-fed rats but is elevated in mice after bile duct ligation (BDL). Hepatic adiponectin protein is lower in steatotic liver but not in the liver of BDL-mice when compared to controls. Adiponectin mRNA was not detected in human liver samples or primary human hepatocytes nor in rat liver but recombinant adiponectin is taken up by isolated hepatocytes in-vitro. AdipoR1 mRNA and AdipoR1 protein levels are similar in the liver tissue of control and fat fed animals whereas AdipoR2 mRNA is induced. AdipoR2 mRNA and AdipoR1 mRNA and protein is suppressed in the liver of BDL-mice.
CONCLUSION: Our studies show reduced circulating adiponectin in a rat model of fatty liver disease whereas circulating adiponectin is elevated in a mouse model of cirrhosis and similar findings have been described in humans. Diminished hepatic expression of adiponectin receptors was only found in liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006986      PMCID: PMC4088231          DOI: 10.3748/wjg.v12.i34.5490

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study.

Authors:  Raj Vuppalanchi; Smitha Marri; Dhanashri Kolwankar; Robert V Considine; Naga Chalasani
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

2.  Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner.

Authors:  Yu Wang; Karen S L Lam; Jian Yu Xu; Gang Lu; Lance Yi Xu; Garth J S Cooper; Aimin Xu
Journal:  J Biol Chem       Date:  2005-02-25       Impact factor: 5.157

Review 3.  Update on nonalcoholic fatty liver disease.

Authors:  Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2002-03       Impact factor: 3.062

4.  Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany.

Authors:  Wolfgang E. Thasler; Thomas S. Weiss; Kerrin Schillhorn; Peter-Tobias Stoll; Bernhard Irrgang; Karl-Walter Jauch
Journal:  Cell Tissue Bank       Date:  2003       Impact factor: 1.522

5.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.

Authors:  Aimin Xu; Yu Wang; Hussila Keshaw; Lance Yi Xu; Karen S L Lam; Garth J S Cooper
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 6.  Cholestasis: human disease and experimental animal models.

Authors:  Emilio Alberto Rodríguez-Garay
Journal:  Ann Hepatol       Date:  2003 Oct-Dec       Impact factor: 2.400

7.  Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis.

Authors:  Roland Buettner; Iris Ottinger; Jürgen Schölmerich; L Cornelius Bollheimer
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-01-13       Impact factor: 4.310

8.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Blood volume in the rat.

Authors:  H B Lee; M D Blaufox
Journal:  J Nucl Med       Date:  1985-01       Impact factor: 10.057

10.  Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity.

Authors:  Atsushi Tsuchida; Toshimasa Yamauchi; Yusuke Ito; Yusuke Hada; Toshiyuki Maki; Sato Takekawa; Junji Kamon; Masaki Kobayashi; Ryo Suzuki; Kazuo Hara; Naoto Kubota; Yasuo Terauchi; Philippe Froguel; Jun Nakae; Masato Kasuga; Domenico Accili; Kazuyuki Tobe; Kohjiro Ueki; Ryozo Nagai; Takashi Kadowaki
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

View more
  16 in total

Review 1.  Adiponectin, a key adipokine in obesity related liver diseases.

Authors:  Christa Buechler; Josef Wanninger; Markus Neumeier
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 2.  Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease.

Authors:  Nikolaos K Gatselis; George Ntaios; Konstantinos Makaritsis; George N Dalekos
Journal:  Clin Exp Med       Date:  2013-01-05       Impact factor: 3.984

3.  High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Chen-Hua Liu; Chi-Lin Chen; Jia-Horng Kao; Ding-Shinn Chen
Journal:  Hepatol Int       Date:  2008-12-02       Impact factor: 6.047

Review 4.  Adiponectin in inflammatory and immune-mediated diseases.

Authors:  Giamila Fantuzzi
Journal:  Cytokine       Date:  2013-07-11       Impact factor: 3.861

Review 5.  Adiponectin action from head to toe.

Authors:  Karine Brochu-Gaudreau; Charlotte Rehfeldt; Richard Blouin; V Bordignon; Bruce D Murphy; Marie-France Palin
Journal:  Endocrine       Date:  2009-12-01       Impact factor: 3.633

6.  Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis.

Authors:  Sebastian Huss; Jörg Schmitz; Diane Goltz; Hans-Peter Fischer; Reinhard Büttner; Ralf Weiskirchen
Journal:  Fibrogenesis Tissue Repair       Date:  2010-06-17

7.  Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis.

Authors:  M Nannipieri; F Cecchetti; M Anselmino; E Mancini; G Marchetti; A Bonotti; S Baldi; B Solito; M Giannetti; A Pinchera; F Santini; E Ferrannini
Journal:  Obes Surg       Date:  2008-10-16       Impact factor: 4.129

8.  Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients.

Authors:  Abby B Siegel; Abhishek Goyal; Marcela Salomao; Shuang Wang; Valerie Lee; Christine Hsu; Rosa Rodriguez; Dawn L Hershman; Robert S Brown; Alfred I Neugut; Jean Emond; Tomoaki Kato; Benjamin Samstein; David Faleck; Raffi Karagozian
Journal:  Oncology       Date:  2014-10-03       Impact factor: 2.935

9.  WAT is a functional adipocyte?

Authors:  Christopher Church; Mark Horowitz; Matthew Rodeheffer
Journal:  Adipocyte       Date:  2012-01-01       Impact factor: 4.534

10.  Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway.

Authors:  Chuanzhao Zhang; Yuan Liao; Qiang Li; Maogen Chen; Qiang Zhao; Ronghai Deng; Chenglin Wu; Anli Yang; Zhiyong Guo; Dongping Wang; Xiaoshun He
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.